Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Jing Li
Sinovac Life Sciences Co., Ltd.
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
179
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Safety and Cross-Reactive Immune Response Against the Omicron Variant of a Third Dose of CoronaVac, and Immune Persistence of Primary Immunization in Healthy Children and Adolescents: Interim Results from a Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trial
Number of pages: 35
Posted: 03 May 2022
Lei Wang
,
Zhiwei Wu
,
Zhifang Ying
,
Minjie Li
,
Yuansheng Hu
,
Qun Shu
, Jing Li,
Qingxia Ma
,
Hengming Zhang
,
Wenbin Jiao
,
Lin Wang
,
Yuliang Zhao
and
Qiang Gao
Sinovac Life Sciences Co., Ltd., Hebei Provincial Center for Disease Control and Prevention, National Institutes for Food and Drug Control, Hebei Provincial Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Beijing Key Tech Statistics Technology Co., Ltd., Sinovac Life Sciences Co., Ltd., Zanhuang County Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Zanhuang County Center for Disease Control and Prevention, Sinovac Life Sciences Co., Ltd., Hebei Provincial Center for Disease Control and Prevention and Sinovac Life Sciences Co., Ltd.
Downloads
179
(422,345)
View PDF
Download
Abstract:
SARS-CoV-2, COVID-19, COVID-19 vaccine booster shot, clinical trial, children and adolescents
Feedback
